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Abstract
Background: Reducing heart rate (HR) in CT angiography of the coronary arteries (CTACor) is critical to image 
quality. The effectiveness of calcium channel blockers as alternatives for patients with contraindications to 
beta-blockers has not been established. 
Objectives: To compare the efficacy in the reduction of HR and RR variability of metoprolol and diltiazem in CTACor. 
Methods: Prospective, randomized, open study that included patients with clinical indication of CTACor in sinus 
rhythm with HR > 70 bpm and no use of agents that could interfere with HR. Fifty patients were randomized 
to the groups: metoprolol IV 5-15 mg or up to HR ≤ 60 bpm (M), and diltiazem IV 0.25 to 0.60 mg/kg or up to 
HR ≤ 60 bpm (D). Blood pressure (BP) and HR were measured at baseline, 1 minute, 3 minutes and 5 minutes after 
the agents, at the acquisition and after CTACor.
Results: HR reduction in absolute values  was higher in group M than in group D (1, 3, 5 min, acquisition and 
post-test). The percentage reduction of HR was significantly higher in group M only 1 min and 3 min after the start 
of the agents. There was no difference in 5 min at acquisition and after examination. The percentage RR variability 
in group D was lower than that in group M during acquisition (RR variability/mean HR of acquisition). A single case 
of AVB, 2:1 Mobitz I occurred, which was spontaneously reverted (group D).
Conclusion: We conclude that diltiazem is an effective and safe alternative to beta-blockers in the reduction of HR when 
performing computed tomography angiography of coronary arteries. (Arq Bras Cardiol 2012;99(2):706-713)
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Recently, a new method for noninvasive assessment 
of coronary arteries using computed tomography (CT) 
equipment, is able to visualize the lumen and the wall of the 
coronary arteries2-5. This method was developed with the 
advent of multiple-detectors computed tomography (MDCT), 
which allowed a much faster image acquisition, and therefore, 
the visualization of the coronary arteries as static images 
without significant motion artifacts. 
While publications of international and multicenter 
studies have validated this technology6-8, demonstrating the 
high accuracy in relation to catheterization, several national9 
and international10 guidelines and consensus documents 
corroborate that computed tomography angiography of 
coronary arteries (CTACor) has important current clinical 
indications, including: patients with intermediate pretest 
probability of CAD unable to exercise; patients with previous 
imaging results that are doubtful or discordant with the clinical 
picture11; evaluation of chest pain in emergency department 
patients with low or intermediate pre-test probability and 
Introduction
Coronary artery imaging is a key element for decision 
management in patients with known or suspected coronary 
artery disease (CAD). The classical method for obtaining 
images of the coronary arteries is invasive catheterization or 
coronary angiography, which, as an invasive procedure, has 
a non-negligible risk of complications and thus is indicated in 
specific cases of high suspicion of CAD or situations of acute 
disease presentation1.  
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normal or doubtful ECG and normal or doubtful markers of 
myocardial necrosis (“enzymes”); evaluation of suspected 
coronary anomalies, among others of great clinical relevance. 
Despite, however, the best temporal resolution of current 
CT equipment, the heart rate (HR) of the patient during image 
acquisition of ATCCor still needs to be around 60 beats per 
minute (< 65 bpm) for the optimal quality of picture and/
or for the radiation dose to be the lowest possible12,13. In 
addition, the RR interval should also be regular for optimal 
image quality, and irregular heartbeats, such as in atrial 
fibrillation and extrasystole, can be extremely damaging to 
image acquisition in CTACor14,15. In the current routine use of 
this test, HR reduction is obtained through the preferential use 
of beta-blockers, either by oral or intravenously administration. 
Intravenous use has been preferred by the majority of services 
in Brazil as it is ease of use, safe and fast-acting, allowing a 
rapid flow of patients at the equipment. 
In the reduction of HR for CTACor, calcium-channel 
blockers are an alternative to beta-blockers in patients with 
contraindications to the latter16. Beta-blockers, even those 
with B1-selective effect, are contraindicated in patients 
with severe asthma or severe chronic obstructive pulmonary 
disease, especially with episodes of bronchoconstriction 
or use of bronchodilators17,18. The acute use of beta-
blockers is also contraindicated in cases of decompensated 
CHF, hypotension (systolic BP < 100 mmHg, advanced 
atrioventricular block, severe aortic stenosis, diabetes at 
risk of hypoglycemia and severe peripheral arterial disease 
(e.g., intermittent claudication, or Raynaud’s disease). Of 
all mentioned contraindications, lung diseases are the most 
commonly found in clinical practice and complications of 
severe bronchoconstriction crisis associated with the acute 
use of beta-blockers are among the most feared. 
One alternative to beta-blockers for HR reduction in 
CTACor and that does not have contraindications in patients 
with bronchoconstriction pulmonary disease are non-
dihydropyridine calcium-channel blockers, such as verapamil 
(fenyl-alquilamines) and diltiazem (benzothiazepines)19. 
However, although mentioned in many texts as an alternative 
to beta-blockers, the efficacy of calcium-channel blockers used 
in the decrease of HR prior to the CTACor has not been clearly 
defined and comparative data are still unavailable. Another 
potential drug for HR reduction in this clinical situation is 
ivabradine, which is only available for oral administration in 
Brazil, as its intravenous form is not yet available for clinical 
use. We participated in an international study with intravenous 
administration of ivabradine, and it showed good results in the 
decrease of HR when performing the CTACor20. 
In the present study, therefore, our objective was to 
evaluate the effectiveness of diltiazem to decrease HR and 
the RR interval variability, when compared to metoprolol in 
patients referred to undergo CTACor. 
Methods 
We designed a prospective, randomized (1:1) and open 
study. Patients with clinical indication of CTACor in sinus 
rhythm and with HR > 70 bpm were included and randomized 
to receive intravenous metoprolol or diltiazem. Metoprolol 
(metoprolol tartrate, Seloken ®) was used at a dose of 5 mg 
in slow intravenous injection, repeated until HR ≤ 60 bpm 
or up to a maximum dose of 15 mg. Diltiazem (diltiazem 
hydrochloride, Balcor ®) was used at a dose of 0.25 mg / kg 
in 2 minutes and HR > 60 bpm, with an additional dose of 
0.35 mg / kg in 2 minutes. We excluded patients using agents 
that interfere with the HR. Thus, we excluded those who 
had prior use of beta-blockers, calcium blockers or any other 
agent that would interfere in the conduction of the AV node 
or that could alter HR. All patients signed a free and informed 
consent form and the study was approved by the institutional 
Ethics Committee.  
Basal HR, as well as systolic, diastolic and mean blood 
pressure (BP) were measured before and 1 minute, 3 minutes 
and 5 minutes after infusion of agents. All measurements were 
repeated after the completion of CTACor. The RR variability 
was measured during the examination acquisition using the 
electrocardiographic tracing of beats recorded during image 
acquisition provided by tomography equipment, in general 
an ECG tracing during 8-12 seconds of the acquisition 
(8-12 beats). The absolute RR variability was defined as the 
difference between the highest and lowest HR, or the largest and 
smallest RR interval and expressed as beats per minute (bpm). 
Thus, a lower variability indicates less difference between the 
minimum and maximum HR during acquisition. The percentage 
RR variability was calculated as the absolute RR variation divided 
by the mean HR during the acquisition of CTACor.    
Patients were followed up to 30 minutes after the 
examination to assess the effects of agents and safety in 
case of possible side effects caused by the examination or 
its preparation. 
As mentioned earlier, HR and BP were measured at 
baseline, before administration of any drug. The assessment 
of HR and BP were repeated 1 minute, 3 minutes and 
5 minutes after the start of agent infusion. Additionally, HR 
was measured during CTACor acquisition (at this moment, 
it was not possible to measure BP), and finally both HR and 
BP were measured again 10 minutes after CTACor. HR was 
measured by the monitor of the electrocardiogram tracing 
and BP was measured with a sphygmomanometer, using the 
traditional auscultatory method. The measurements were 
performed with the patient in the supine position on the 
table of MDCT equipment. 
We also calculated the percentage reduction of HR in 
relation to basal HR of each patient, thus normalizing the 
effects of drugs for initial HR of each patient, which showed 
significant variation. 
The CTACor used a standard protocol for image acquisition 
in MDCT equipment with 64-detector columns (Aquilion 64, 
Toshiba Medical Systems, Otawara, Japan) and injection of 
nonionic iodinated contrast at the time of acquisition. This 
protocol was described in a previous study21.
The statistical analysis used the Shapiro-Wilk test to 
determine whether the distribution was normal. For variables 
with normal distribution, Student’s t test for two means 
with similar variance was used to compare the HR in both 
groups of agents at each moment in time. For variables with 
nonparametric distribution, the Kruskal-Wallis test was used. 
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Results
We selected 126 consecutive patients referred to the 
Department of Magnetic Resonance and Cardiovascular 
Computed Tomography of our institution with CTACor 
clinical indication. Seventy-six patients were excluded due to 
some exclusion criteria: current use of any agent that could 
cause bradycardia or interfere with the conduction of the 
AV node; cardiac rhythm other than sinus, HR < 70 bpm. 
Thus 50 consecutive patients were included, 38 men (76%) 
and 12 women (38%) with a mean age of 57.8 ± 6.7 years. 
Patients were randomized to the metoprolol (M) or diltiazem 
(D) group, with 25 patients in each group. 
Only six patients (24%) from group D received 0.25 mg/kg 
of diltiazem and the other 19 patients (76%) received a 
total dose of 0.6 mg/kg. The mean dose of diltiazem was 
0.15 ± 0.516 mg/kg. In group M, eight patients received 
5 mg, eight patients received 10 mg and nine patients 
received 15 mg of metoprolol. The mean dose of metoprolol 
was 10.2 ± 4.2 mg. 
No patient developed symptoms during or after the infusion 
of agents. Two patients had frequent ventricular extrasystoles 
at baseline, both from group D. After the infusion of agents 
and during or after the acquisition of CTACor, four patients 
had ventricular extrasystoles (the same two patients who had 
them at baseline and two patients without prior arrhythmia, 
also from group D). One patient from group M showed 
significant worsening of sinus arrhythmia during acquisition, 
with significant RR variability of 10 beats, thus impairing 
image acquisition. One patient from group D showed second-
degree AV block, Mobitz I 2:1, without any symptoms or 
hemodynamic effects, which reverted spontaneously during 
patient follow-up (after 10 minutes). 
Basal HR was similar between groups. HR at 1 minute, 
3 minutes, 5 minutes, acquisition and post-CTACor were 
significantly lower in group M, when compared with group 
D, especially at 1 minute, 3 minutes and 5 minutes (Table 1). 
Minimum and maximum HR values are shown in Table 1. 
Figure 1 shows all points of all patients with the temporal 
evolution of HR, in both groups. Figure 2 shows the curve 
of predicted HR using fractional polynomial fit, for each 
point and its confidence interval, for both groups.
If we consider the percentage reduction in relation 
to basal HR, we will normalize the data for initial HR of 
each patient, which showed significant variation. Thus, 
the percentage reduction in HR was higher in group M 
when compared to group D, only at the first and third 
minutes, no longer significant at the fifth minute, acquisition 
and post-CTACor (Table 2). The absolute RR variability 
showed a trend toward less variability in group D, while 
the percentage variability (RR variability / mean HR of 
the acquisition) was statistically lower in group D when 
compared to group M during the acquisition (Table 3).
BP behavior is shown in Tables 4, 5 and 6. After the 
start of intravenous drug injection, the BP decreased and 
recovered in the post-acquisition period. The BP decreases 
were slight and did not result in any hypotension symptoms 
in any patient. In general, the D group showed lower BP even 
at baseline and remained more hypotensive throughout the 
monitoring period when compared to group M. 
Discussion
The CTACor by intravenous injection of nonionic 
iodinated contrast al lows the detailed anatomical 
visualization of the coronary arteries, vascular grafts 
(mammary and saphenous vein bypass grafts) and intra- 
and extracardiac structures, such as valves, thrombi 
and pericardium. As mentioned earlier, the acquisition 
and reconstruction of CTACor images are performed 
synchronously with the electrocardiographic signal. 
Therefore, the optimized image acquisition depends on the 
HR control of patients, to improve the diagnostic quality 
and the use of the lowest possible radiation dose14,15. 
In 64-detector devices, the patients must have regular 
HR, as data is obtained in different heartbeats (usually 
six to eight), and then combined into a single volume. 
Thus, if there are irregularities between RR intervals, the 
combined data that were acquired at different phases of the 
cardiac cycle result in “steps” and/or movement artifacts. 
In addition, a low and regular HR allows the use of dose 
modulation algorithms connected to the ECG, where the 
higher dose of X-ray is released only during diastole, or 
even the use of prospective acquisition (with fewer images 
from the device), which can reduce the radiation dose by 
60%. In more modern devices, which are still rare in our 
country, image acquisition is performed during only one 
or two beats.
Nevertheless, the use of negative chronotropic agents is 
important. Although less critical, controlling the HR is still 
used almost universally in order to take full advantage of its 
dose reduction capacity, which can become smaller than 
 Table 1 – Minimum, mean and maximum Heart Rate (HR) – temporal evolution in the groups
Mean HR (bpm) Basal 1 min 3 min 5 min Acquisition Post
Metoprolol 80.0 ± 6.1 69.3 ± 6.2 65.3 ± 5.7 63.6 ± 6.6 62.6 ± 8.5 70.2 ± 6.6
Diltiazem 83.4 ± 8.4 76.8 ± 7.7 73.0 ± 7.2 68.7 ± 6.4 68.5 ± 9.1 75.0 ± 9.3
p 0.11 0.0004 0.0001 0.0071 0.0215 0.0396
HR Min-Max (bpm)
Metoprolol 70 - 96 58 - 86 56 - 80 54 - 79 50 - 81 60 - 82
Diltiazem 72 - 108 58 - 90 56 - 86 55 - 82 54 - 96 61 - 102
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Figure 1  – Line graph illustrating the temporal evolution of heart rate for all patients in both groups, metoprolol, and diltiazem.
HR
 (b
pm
)
Acquisition Acquisition Post
HR in time per agent
5 min3 min1 minBasalPost5 min3 minBasal 1 min
Figure 2 – Gráfico demonstrando a evolução temporal da frequência cardíaca predita e o intervalo de confiaça de 95%, num ajuste de curva utilizando um polinomial 
fracional, em ambos os grupos, metoprolol e diltiazem.
95%CI HR
Acquisition Acquisition Post5 min3 min1 minBasalPost5 min3 minBasal 1 min
HR in time per agent
Time
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1mSv (approximately 10 plain chest X-rays)22. Protocols 
vary depending on the services, but the target HR  on 
acquisition is  below 65 bpm. When the patient arrives for 
the examination with a HR > 65 bpm, invariably he or she 
will receive medication to control HR. 
The group of agents initially used to control HR is 
the beta-blockers, by premedication, by oral route, 
approximately one hour before the examination, or 
intravenously immediately prior to it. However, some 
studies that analyzed the performance of this strategy found 
surprisingly high rates (27% to 34%) of patients who did not 
reach the target HR, even after oral premedication and the 
use of maximum dose (20 mg) of the most commonly used 
intravenous beta-blocker, metoprolol. Furthermore, there 
was a high number (16%) of patients with some degree of 
contraindication to the use of this class of agents. 
All this contributes to the poorer quality of diagnostic 
images and explains the need for alternative strategies 
and drugs23,24. The following are contraindications to 
beta-blockers, selective or not: presence of advanced 
atrioventricular block, hypotension, asthma, Chronic 
Obstructive Pulmonary Disease (COPD) and clinical 
Table 2 – Percentage decrease in heart rate in relation to basal HR
Decrease / basal HR (%) 1 min 3 min 5 min Acquisition Post
Metoprolol 13.2 ± 6.1 18.1 ± 6.7 20.4 ± 6.9 21.7 ± 8.9 12.0 ± 7.6
Diltiazem 7.6 ± 8.2 12.2 ± 6.6 17.3 ± 6.3 17.7 ± 7.7 9.9 ± 7.8
p 0.0085 0.003 0.1012 0.0964 0.3266
Table 3 – Variability of the RR interval – absolute and percentage of mean HR of acquisition
RR Variability Absolute, mean [min-max] (bpm) % of  mean HR of Acquisition
Metoprolol 5.7 ± 2.8 [2 - 11] 9.4 ± 5.2
Diltiazem 4.3 ± 2.9 [0 - 12] 6.2 ± 4.0
p 0.0891 0.0174
Table 4 – Systolic Blood Pressure (SBP) – temporal evolution in the groups
SBP (mmHg) basal 1 min 3 min 5 min Post
Metoprolol 139.2 ± 25.0 132.0 ± 23.1 128.5 ± 23.1 125.9 ± 24.0 129.4 ± 21.5
Diltiazem 130.4 ± 16.0 116.5 ± 10.0 116.7 ± 10.7 117.0 ± 8.9 119.4 ± 15.2
p 0.1428 0.0035 0.0247 0.0876 0.0685
Table 5 – Diastolic Blood Pressure (DBP) – temporal evolution in the groups
DBP (mmHg) basal 1 min 3 min 5 min Post
Metoprolol 85.2 ± 10.1 82.2 ± 11.2 80.3 ± 11.1 78.9 ± 9.9 80.5 ± 10.5
Diltiazem 78.7 ± 9.4 72.7 ± 10.6 73.6 ± 8.8 73.0 ± 8.5 75.2 ± 9.9
p 0.0222 0.0035 0.0228 0.0279 0.0762
Table 6 – Mean Arterial Pressure (MAP) – temporal evolution in the groups
MAP (mmHg) basal 1 min 3 min 5 min Post
Metoprolol 103.2 ± 14.1 98.8 ± 14.1 96.2 ± 14.3 94.5 ± 13.7 97.7 ± 13.7
Diltiazem 95.9 ± 10.1 87.4 ± 9.0 87.9 ± 8.0 87.6 ± 6.9 89.8 ± 10.0
p 0.0395 0.0017 0.0148 0.0279 0.0486
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instability 16. Although there have been studies demonstrating 
the safety of chronic use of low-dose selective beta-blockers 
by oral administration in patients with COPD25, the 
acute intravenous use for CTACor, especially in patients 
using beta-adrenergic agents such as bronchodilators, is 
still considered a contraindication from the clinical and 
pharmacological point of view, and literature studies that 
tested this particular situation are not available.  
Calcium-channel blockers, particularly diltiazem, may be 
used in cases of patients with pulmonary disease, being a 
simple, efficient and widely available alternative to control 
HR16. Calcium-channel blockers decrease conduction through 
the AV node and to a lesser extent, in the sinoatrial node26. 
Due to this mechanism, they are the group of choice for pre-
examination control of patients with atrial fibrillation27. They 
do not induce bronchospasm, but have a less intense negative 
chronotropic effect. Among them, diltiazem should preferably 
be chosen, as it has a lower negative inotropic effect.
The recommended dose of diltiazem is 0.25 mg/kg, IV 
route, in 2 minutes, and a second dose of 0.35 mg/kg, may be 
administered if the target HR is not attained. Our results suggest 
that the second dose is usually required to achieve the target 
HR. Thus, the first dose can be administered in the preparation 
room and the second in the examination room. In some cases in 
clinical practice, when the patient arrives at the service with high 
HR (> 90 bpm), to facilitate management strategy we calculate 
a maximum dose of 0.6 mg/kg and infuse the medication for 
15-20 minutes, diluted with 100 mL of saline solution. 
The present study was one of the first to investigate, in 
a controlled manner, the use of diltiazem for ATCCor and 
to compare results with beta-blockers. A direct comparison 
between the major drugs, metoprolol and diltiazem, 
is scarce in the literature. In this study we observed a 
significant reduction in HR after 1, 3 and 5 minutes of drug 
infusion, both in patients who received beta-blockers and 
those who received diltiazem, with a higher reduction in the 
first group; however, statistical significance was observed 
only in the third minute and not at the end of infusion. 
We also observed the safety when using diltiazem in the 
context of CTACor. Blood pressure after the test was similar 
in both groups (despite the theoretical greater vasodilation 
with calcium-channel blockers) and there were no reports 
of major disturbances in heart rhythm.
A very important and original data investigated in this 
study was that patients receiving diltiazem had significantly 
lower variability of the RR interval during CTACor 
acquisition, which is an extra advantage for the quality of 
acquired images at the coronary angiography, particularly 
in equipment with 64-detector columns.  
The combined use of beta blockers and diltiazem is not 
recommended for routine use, due to the potential to cause 
bradyarrhythmias. However, in some specialized centers and 
in selected patients, when the highest dose of beta-blockers 
is achieved and HR remains well above the target, a dose 
of 0.25 mg/ kg of diltiazem has been associated, allowing 
the acquisition below 70 bpm, with no record of problems. 
In this case, the patient remains under observation after the 
examination during the half-life of diltiazem elimination, 
which is 3.5 to 4.5 hours (authors’ personal experience). 
Every center that carries out the examination should be 
prepared with equipment and personnel trained in advanced 
life support in cardiology to treat potential complications such 
as hypotension and bradycardia. Basic treatment includes 
high volume administration and lower-limb elevation. 
The antidotes glucagon (for beta-blockers) and calcium 
gluconate or chloride should also be available, in addition 
to atropine and vasopressors for cases of extreme gravity, 
which fortunately are very rare.
In short, there was effective decrease in HR in both groups, 
with a greater reduction in the metoprolol group. In turn, the 
smaller RR variability during the examination acquisition with 
diltiazem, associated with its coronary vasodilator effect is an 
inherent characteristic of the drug, which can offer advantages 
over the classical use of beta-blockers. It is noteworthy, 
however, that in the present study we did not perform a direct 
evaluation of the quality of images obtained in both groups. As 
there have been several studies showing a direct association 
between the degree of HR reduction and the final quality of 
the images13-15, in the present study we chose to restrict our 
investigation to an indirect assessment of the effect of HR 
control agents on the final quality of images. 
Nevertheless, it is important to recognize that this issue 
represents an important limitation, and that further studies 
should be performed in order to more specifically clarify the 
association between the type of drug used to control HR 
and the final quality of images. Therefore, we would have 
definitive proof that diltiazem is an effective alternative to 
beta-blockers in this clinical context.  
Finally, the present randomized clinical trial showed 
that, in the clinical situation of CTACor examinations, HR 
reduction was greater with diltiazem, when compared to 
metoprolol. Diltiazem showed lower RR variability during 
image acquisition when compared to metoprolol, which is 
also associated with better image quality. Overall, diltiazem 
showed to be an effective and safe alternative to beta-
blockers in reducing HR prior to angiography by computed 
tomography of the coronary arteries.
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